var data={"title":"Hydroxyurea (hydroxycarbamide): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydroxyurea (hydroxycarbamide): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6345?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">see &quot;Hydroxyurea (hydroxycarbamide): Drug information&quot;</a> and <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydroxyurea (hydroxycarbamide): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708910\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression (Droxia, Siklos):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydroxyurea may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Secondary malignancy (Droxia, Siklos):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181021\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Droxia;</li>\n      <li>Hydrea</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181022\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Hydrea</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047762\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047754\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">see &quot;Hydroxyurea (hydroxycarbamide): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses should be based on ideal or actual body weight, whichever is less (per manufacturer).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Sickle cell anemia:</b> Limited data available: Infants &ge;6 months, Children, and Adolescents: Oral: 20 mg/kg/dose once daily; may increase by 5 mg/kg/<b>day</b> every 8 weeks until mild myelosuppression (target ANC 2,000 to 4,000/mm<sup>3 </sup>[ANC of 1,500/mm<sup>3 </sup> has been used in some studies]) is achieved; maximum dose: 35 mg/kg/<b>day</b> (Hankins 2005; NHLBI 2014; Strouse 2012, Thornsburg 2009, Wang 2001, Wang 2011); <b>Note</b>: Initial starting dose of 15 mg/kg/dose once daily have also been studied (Kinney 1999, Zimmerman 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If myelosuppression occurs (platelets &lt;80,000/mm<sup>3</sup>, neutrophils &lt;2,000/mm<sup>3</sup>; younger patients with lower baseline counts may safely tolerate ANC down to 1,250/mm<sup>3</sup>), hold therapy until counts recover (monitor weekly); reinitiate at a dose 5 mg/kg/day lower than the dose given prior to onset of cytopenias (NHLBI 2014); some have recommended reinitiating at a dose 2.5 mg/kg/day lower (Hankins 2005; Heeney 2008; Wang 2001; Wang 2011; Zimmerman 2004).<b> Note:</b> A clinical response to treatment may take 3 to 6 months; a 6-month trial of the maximum tolerated dose is recommended prior to considering discontinuation due to treatment failure; effectiveness of hydroxyurea depends upon daily dosing adherence. For patients who have a clinical response, long-term hydroxyurea therapy is indicated (NHLBI 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antineoplastic uses:</b> Titrate dose to patient response; if WBC count falls to &lt;2,500/mm<sup>3</sup>, or the platelet count to &lt;100,000/mm<sup>3</sup>, therapy should be stopped for at least 3 days and resumed when values rise toward normal.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ASCO guidelines for chemotherapy dosing in obese adults with cancer: Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012). <b>Note:</b> The manufacturer recommends dosing based on ideal or actual body weight, whichever is less.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Chronic myelocytic leukemia (resistant):</b> Oral: Continuous therapy: 20 to 30 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Solid tumors (head and neck cancer, melanoma, ovarian cancer):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent therapy: 80 mg/kg as a single dose every third day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous therapy: 20 to 30 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Concomitant therapy with irradiation (head and neck cancer): 80 mg/kg as a single dose every third day starting at least 7 days before initiation of irradiation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sickle cell anemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Initial: 15 mg/kg/day as a single dose; if blood counts are in an acceptable range, may increase by 5 mg/kg/day every 12 weeks until the maximum tolerated dose of 35 mg/kg/day is achieved or the dose that does not produce toxic effects (do not increase dose if blood counts are between acceptable and toxic ranges). Monitor for toxicity every 2 weeks; if toxicity occurs, withhold treatment until the bone marrow recovers, then restart with a dose reduction of 2.5 mg/kg/day; if no toxicity occurs over the next 12 weeks, then the subsequent dose may be increased by 2.5 mg/kg/day every 12 weeks to a maximum tolerated dose (dose which does not produce hematologic toxicity for 24 consecutive weeks). If hematologic toxicity recurs a second time at a specific dose, do not retry that dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Acceptable hematologic ranges:</i> Neutrophils &ge;2,500/mm<sup>3</sup>; platelets &ge;95,000/mm<sup>3</sup>; hemoglobin &gt;5.3 g/dL, and reticulocytes &ge;95,000/mm<sup>3</sup> if the hemoglobin concentration is &lt;9 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Toxic hematologic ranges:</i> Neutrophils &lt;2,000/mm<sup>3</sup>; platelets &lt;80,000/mm<sup>3</sup>; hemoglobin &lt;4.5 g/dL; and reticulocytes &lt;80,000/mm<sup>3</sup> if the hemoglobin concentration is &lt;9 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations: Initial: 15 mg/kg/day; if dosage escalation is warranted based on clinical/laboratory findings, may increase by 5 mg/kg/day increments every 8 weeks. Monitor for toxicity at least every 4 weeks when adjusting dose; aim for a target absolute neutrophils &ge;2,000/mm<sup>3</sup> (younger patients with lower baseline counts may safely tolerate absolute neutrophils down to 1,250/mm<sup>3</sup>; maintain platelet count &ge;80,000/mm<sup>3</sup>. Give until mild myelosuppression is achieved (absolute neutrophils: 2,000/mm<sup>3</sup> to 4,000/mm<sup>3</sup>), up to a maximum dose of 35 mg/kg/day. If toxicity occurs (neutropenia or thrombocytopenia), withhold treatment until the bone marrow recovers (monitor weekly), then restart at a dose 5 mg/kg/day lower than the dose given prior to onset of cytopenias (NHLBI 2014). <b>Note:</b> A clinical response to treatment may take 3 to 6 months; a 6-month trial on the maximum tolerated dose is recommended prior to considering discontinuation due to treatment failure; effectiveness of hydroxyurea depends upon daily dosing adherence. For patients who have a clinical response, long-term hydroxyurea therapy is indicated (NHLBI 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cutaneous vasculitic ulcerations: Discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal toxicity (severe nausea, vomiting, anorexia): Temporarily interrupt treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mucositis (severe): Temporarily interrupt treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pancreatitis: Discontinue permanently</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Antineoplastic uses (CML, head and neck cancer, melanoma, ovarian cancer):</b> WBC &lt;2,500/mm<sup>3</sup> or platelets &lt;100,000/mm<sup>3</sup>: Interrupt treatment (for at least 3 days), may resume when values rise toward normal</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Sickle cell anemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: Neutrophils &lt;2,000/mm<sup>3</sup>, platelets &lt;80,000/mm<sup>3</sup>, hemoglobin &lt;4.5 g/dL, or reticulocytes &lt;80,000/mm<sup>3</sup> with hemoglobin &lt;9 g/dL: Interrupt treatment; following recovery, may resume with a dose reduction of 2.5 mg/kg/day. If no toxicity occurs over the next 12 weeks, subsequent dose may be increased by 2.5 mg/kg/day every 12 weeks to a dose which does not produce hematologic toxicity for 24 consecutive weeks. If hematologic toxicity recurs a second time at a specific dose, do not retry that dose.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate recommendations: Absolute neutrophils &lt;2,000/mm<sup>3</sup> (younger patients with lower baseline counts may safely tolerate absolute neutrophils down to 1,250/mm<sup>3</sup>), platelets &lt;80,000/mm<sup>3</sup>: Interrupt treatment; following recovery, may restart at a dose 5 mg/kg/day lower than the dose given prior to onset of cytopenias (NHLBI 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The following guidelines have been used by some clinicians: Reduce initial dose to 15 mg/kg/dose once daily (Heeney 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Sickle cell anemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;60 mL/minute: No adjustment (of initial dose) required</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;60 mL/minute: Reduce initial dose to 7.5 mg/kg/day (Yan 2005); titrate to response/avoidance of toxicity (refer to usual dosing)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">ESRD: Reduce initial dose to 7.5 mg/kg/dose (administer after dialysis on dialysis days); titrate to response/avoidance of toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Other approved indications:</b> It is recommended to reduce the initial dose; however, no specific guidelines are available.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following guidelines have been used by some clinicians:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aronoff 2007: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 10 to 50 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute: Administer 20% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: Administer dose after dialysis on dialysis days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous renal replacement therapy (CRRT): Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">NHLBI 2014: Sickle cell anemia: Adults: Chronic kidney disease: Initial 5 to 10 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Kintzel 1995:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 46 to 60 mL/minute: Administer 85% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 31 to 45 mL/minute: Administer 80% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;30 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: There are no dosage adjustments provided in the manufacturer's labeling; closely monitor for bone marrow toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180998\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Droxia: 200 mg, 300 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Droxia: 400 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hydrea: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180983\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50964559\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Droxia: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016295s049s050lbl.pdf#page=15&amp;token=xp3qlqdSFlgKdLm+woZmjMMUJILPQqwrYf7RZv52lv9ydBTr+cGxL6KP/64y53jBGgv1rCUmlEkS54I1aAJBD7TVC1tC7LfRdgmBj6IvVtkLqjnIiy0Zfy1Z8f8JnX/P&amp;TOPIC_ID=13367\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016295s049s050lbl.pdf#page=15</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Siklos: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf#page=17&amp;token=ieHGobpnwoqBZaCeBlVs4FSL8UsZPIYwreEyyOq7JbmSbNqnqTQVajJDnPokwNqc5mJ5I0uusKDQbxOl1bzwaqmR/G8yXj9tFyOhHnPdsz1C2lg5C2if1ZL4OfXLhnVf&amp;TOPIC_ID=13367\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf#page=17</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047766\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: The manufacturer does not recommend opening the capsules; observe proper handling procedures (eg, wear gloves). Doses rounded to the nearest 100 mg when using capsules allows for dosing accuracy within ~2 mg/kg/day (Heeney 2008). For patients unable to swallow capsules, an oral solution may be prepared. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132627\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181017\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Keep bottle tightly closed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047765\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of refractory chronic myelocytic leukemia (CML), melanoma, and recurrent, metastatic, or inoperable ovarian carcinoma (Hydrea: FDA approved in adults); treatment of primary squamous cell carcinomas of the head and neck with radiation (excluding lip cancer) (Hydrea: FDA approved in adults); management of sickle cell anemia in patients who have had at least three painful crises in the previous 12 months (to reduce frequency of these crises and the need for blood transfusions) (Droxia: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181070\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydrea may be confused with Lyrica</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydroxyurea may be confused with hydroxychloroquine, hydrOXYzine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydrea [US, Canada, and multiple international markets] may be confused with Hydra brand name for isoniazid [Japan]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181067\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, hypersensitivity angiitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, disorientation, dizziness, drowsiness (dose-related), hallucination, headache, malaise, peripheral neuropathy (HIV-infected patients), seizure, vasculitic ulcerations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, atrophy of nail, changes in nails, dermal ulcer, dermatomyositis-like skin changes, desquamation, eczema, erythema (peripheral), facial erythema, gangrene of skin or other tissue, hyperpigmentation, leg ulcer, maculopapular rash, nail discoloration, papule (violet), skin atrophy, skin carcinoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased uric acid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Acute mucocutaneous toxicity, anorexia, BSP abnormality (retention), constipation, diarrhea, gastric distress, gastrointestinal irritation (potentiated with radiation therapy), mucositis (potentiated with radiation therapy), nausea, oral mucosa ulcer, pancreatitis (HIV-infected patients), stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Abnormal erythropoiesis (megaloblastic; self-limiting), bone marrow depression (neutropenia, thrombocytopenia; hematologic recovery: within 2 weeks), leukemia (secondary; long-term use), leukopenia, macrocytosis, reticulocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic failure (HIV-infected patients), hepatotoxicity, increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Panniculitis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, renal tubular disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, dyspnea, pulmonary fibrosis (rare), pulmonary infiltrates (diffuse, rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Actinic keratosis (Antonioli 2012), azoospermia, basal cell carcinoma (Antonioli 2012), cholestasis, hepatitis, hyperkeratosis (Antonioli 2012), lesion (dyschromic [Antonioli 2012]), malignant neoplasm (Wong 2014), mucous membrane lesion (Antonioli 2012), oligospermia, pneumonitis (Antonioli 2012), squamous cell carcinoma (Antonioli 2012), tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181005\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Hypersensitivity to hydroxyurea or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe bone marrow depression (eg, leukopenia [&lt;2,500/mm<sup>3</sup>], thrombocytopenia [&lt;100,000/mm<sup>3</sup>], or severe anemia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180987\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression:<b> [US Boxed Warning]: Hydroxyurea may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary.</b> Leukopenia and neutropenia commonly occur (thrombocytopenia and anemia are less common); leukopenia/neutropenia occur first. Severe or life-threatening myelosuppression may occur at the recommended initial dose. Hematologic toxicity is reversible (rapid) with treatment interruption; after treatment interruption, resume therapy at a lower dose. Use with caution in patients with a history of prior chemotherapy or radiation therapy; myelosuppression is more common. Correct severe anemia prior to initiating treatment. Do not initiate therapy if bone marrow function is markedly reduced. Pediatric patients are at increased risk for myelosuppression at the time of dosage adjustments due to changes in body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous vasculitic toxicities: Vasculitic ulcerations and gangrene have been reported in patients with myeloproliferative disorders during hydroxyurea treatment, most often in patients with a history of or receiving concurrent interferon therapy. Discontinue hydroxyurea (or reduce the dose) and consider alternate cytoreductive therapy if cutaneous vasculitic toxicity develops. Ulcers may rarely be caused by leukocytoclastic vasculitis. Avoid use in patients with leg ulcer wounds.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Drug-induced fever has been reported (with cardiovascular, dermatologic, GI, hepatic, musculoskeletal, or pulmonary manifestations); may require hospitalization. The onset is usually within 6 weeks of treatment initiation and resolves with discontinuation. Fever usually recurred within 24 hours with re-challenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Macrocytosis: Self-limiting macrocytosis may be seen early in treatment (may resemble pernicious anemia, but is unrelated to vitamin B<sub>12</sub> or folic acid deficiency). May mask diagnosis of pernicious anemia. Prophylactic folic acid supplementation is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: <b>[US Boxed Warning]: Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies.</b> Treatment of myeloproliferative disorders (eg, polycythemia vera, thrombocythemia) with long-term hydroxyurea is associated with secondary leukemia; it is unknown if this is drug-related or disease-related. Skin cancer has been reported with long-term hydroxyurea use. Monitor for signs/symptoms of secondary malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Hyperuricemia may occur with antineoplastic treatment; adequate hydration and initiation or dosage adjustment of uricosuric agents (eg, allopurinol) may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV-infected patients: Pancreatitis, hepatotoxicity, and peripheral neuropathy have occurred when hydroxyurea was administered with antiretroviral medications, including didanosine and stavudine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may require dose reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concurrent drug therapy issues: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: May be more sensitive to the effects of hydroxyurea; may require lower doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation therapy recipients: Patients with a history of radiation therapy are at risk for exacerbation of post irradiation erythema and myelosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Avoid use of live vaccines during hydroxyurea therapy. Concomitant use may potentiate viral replication and may possibly increase vaccine adverse reactions due to suppression of normal defense mechanisms by hydroxyurea and result in severe infections. The antibody response to vaccines may be decreased. Consider consultation with a specialist if immunization with a live vaccine is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299494\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180992\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13367&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: May enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Hydroxyurea may enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stavudine: Hydroxyurea may enhance the adverse/toxic effect of Stavudine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Stavudine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181009\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. Based on its mechanism of action, hydroxyurea may cause fetal harm if administered during pregnancy. Women of reproductive potential should be advised to avoid becoming pregnant during treatment (verify pregnancy status prior to starting hydroxyurea therapy) and should use effective contraception during and for at least 6 months after completion of therapy. Hydroxyurea use may damage spermatozoa and testicular tissue; males with female partners of reproductive potential should use effective contraception during and for at least 6 months (Siklos) or 1 year (Droxia, Hydrea) after therapy. Azoospermia or oligospermia (sometimes reversible) has been observed in male patients; counsel males of reproductive potential about sperm banking prior to therapy initiation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047761\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">General: CBC with differential, liver function tests and renal function should be checked at baseline and then periodically throughout therapy; serum uric acid, signs and symptoms of pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sickle cell anemia: Monitor hemoglobin F levels. During dose escalation, monitor for toxicity every 2 weeks (neutrophils, platelets, hemoglobin, reticulocytes) per manufacturer's labeling, or at least every 4 weeks when adjusting the dose (CBC with WBC differential, reticulocytes) [NHLBI 2014]). Once on a stable dose, may monitor CBC with differential, reticulocyte count and platelets every 2 to 3 months (NHLBI 2014). Monitor RBC, MCV (mean corpuscular volume) and HbF (fetal hemoglobin) levels for evidence of consistent or progressive laboratory response (NHLBI 2014). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180986\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Hydroxyurea is an antimetabolite that selectively inhibits ribonucleoside diphosphate reductase, preventing the conversion of ribonucleotides to deoxyribonucleotides, halting the cell cycle at the G1/S phase and therefore has radiation sensitizing activity by maintaining cells in the G<sub>1</sub> phase and interfering with DNA repair. In sickle cell anemia, hydroxyurea increases red blood cell (RBC) hemoglobin F levels, RBC water content, deformability of sickled cells, and alters adhesion of RBCs to endothelium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181004\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> In pediatric patients, large interpatient variability and phenotypic differences have been reported (Ware 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset: Sickle cell anemia: Fetal hemoglobin increase: 4 to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Readily absorbed  (&ge;80%); relatively rapid (Rodriguez 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes widely into tissues (including into the brain); estimated volume of distribution approximates total body water (Gwilt 1998); concentrates in leukocytes and erythrocytes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: Children: ~12 L (range: 2.5 to 52) (Ware 2011); Adults: ~20 L/m<sup>2</sup> (Rodriguez 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Up to 60% via hepatic metabolism and urease found in intestinal bacteria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~100% (Rodriguez 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 75% to 80% bound to serum proteins (Gwilt 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1.9 to 3.9 hours (Gwilt 1998); Children: Sickle cell anemia: 1.7 hours (range: 0.7 to 3 hours) (Ware 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Children: &quot;Fast&quot; phenotype: 15 to 30 minutes; &quot;Slow&quot; phenotype: 60 to 120 minutes (Ware 2011); Adults: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (sickle cell anemia: ~40% of administered dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Children: ~7 L/hour (range: 1.6 to 22) (Ware 2011); Adults: ~7.5 L/hour (Rodriguez 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10528705\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>100 mg/mL Oral Solution (ASHP Standard Concentration) </b>(ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 100 mg/mL oral solution may be prepared with capsules. Mix the contents of twenty 500 mg capsules with enough room temperature sterile water (~50 mL) to initially result in a 200 mg/mL concentration. Stir vigorously using a magnetic stirrer for several hours, then filter to remove insoluble contents. Add 50 mL Syrpalta (flavored syrup without color, HUMCO) to filtered solution, resulting in 100 mL of a 100 mg/mL hydroxyurea solution. Stable for 1 month at room temperature in amber plastic bottle (Heeney 2004).</p>\n    <div class=\"reference\">Heeney MM, Whorton MR, Howard TA, et al. Chemical and functional analysis of hydroxyurea oral solutions. <i>J Pediatr Hematol Oncol.</i> 2004;26(3):179-184.<span class=\"pubmed-id\">15125610</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181008\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Droxia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $54.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (60): $54.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (60): $58.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Hydrea Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $163.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Hydroxyurea Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $127.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181010\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Biosupressin (HU);</li>\n      <li>Cytodrox (ID, JO, LK);</li>\n      <li>Droxamida (PE);</li>\n      <li>Hidrolid (AR);</li>\n      <li>Hidroxicarbamida (CL);</li>\n      <li>Hydab (PH);</li>\n      <li>Hydrea (AU, BB, BE, BG, BR, CL, CO, DK, EE, EG, ES, FI, GB, GR, HK, ID, IE, JP, KR, LT, LU, MT, MX, NL, NO, NZ, PK, RU, SE, TH, TW, UY, VN, ZA);</li>\n      <li>Hydrine (SG);</li>\n      <li>Hydronix (BD);</li>\n      <li>Hydroxycarbamid (PL);</li>\n      <li>Hydroxyurea medac (PL, SE);</li>\n      <li>Hytinon (VN);</li>\n      <li>Krabinex (PH);</li>\n      <li>Litalir (AT, CH, CZ, HN, HR, HU);</li>\n      <li>MPL Hi-Oxy (PH);</li>\n      <li>Neodrea (IN);</li>\n      <li>Onco-Carbide (IT);</li>\n      <li>Siklos (ES, FR, GB, TR);</li>\n      <li>Syrea (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. <i>Am J Hematol</i>. 2012;87(5):552-554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/22473827/pubmed\" target=\"_blank\" id=\"22473827\">22473827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed., Philadelphia, PA: American College of Physicians, 2007, 100.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Droxia capsule (hydroxyurea) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferster A, Tahriri P, Vermylen C, et al, &ldquo;Five Years of Experience With Hydroxyurea in Children and Young Adults With Sickle Cell Disease,&rdquo; <i>Blood</i>, 2001, 97(11):3628-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/11369660/pubmed\" target=\"_blank\" id=\"11369660\">11369660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline.<i> J Clin Oncol</i>. 2012;30(13):1553-1561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gwilt PR and Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. <i>Clin Pharmacokinet</i>. 1998;34(5):347-358.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/9592619/pubmed\" target=\"_blank\" id=\"9592619\">9592619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hankins JS, Ware RE, Rogers ZR, et al, &ldquo;Long-Term Hydroxyurea Therapy for Infants With Sickle Cell Anemia: The HUSOFT Extension Study,&rdquo; <i>Blood</i>, 2005, 106(7):2269-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/16172253/pubmed\" target=\"_blank\" id=\"16172253\">16172253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heeney MM and Ware RE, &quot;Hydroxyurea for Children With Sickle Cell Disease,&quot; <i>Pediatr Clin North Am</i>, 2008, 55(2):483-501.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/18381097/pubmed\" target=\"_blank\" id=\"18381097\">18381097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heeney MM, Whorton MR, Howard TA, et al, &ldquo;Chemical and Functional Analysis of Hydroxyurea Oral Solutions,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2004, 26(3):179-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/15125610/pubmed\" target=\"_blank\" id=\"15125610\">15125610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-Boluda JC1, Alvarez-Larr&aacute;n A, G&oacute;mez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. <i>Br J Haematol</i>. 2011;152(1):81-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/21083657/pubmed\" target=\"_blank\" id=\"21083657\">21083657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. <i>Blood</i>. 1999;94(5):1550-1554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/10477679/pubmed\" target=\"_blank\" id=\"10477679\">10477679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &quot;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&quot; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maier-Redelsperger M, de Montalembert M, Flahault A, et al, &ldquo;Fetal Hemoglobin and F-Cell Responses to Long-Term Hydroxyurea Treatment in Young Sickle Cell Patients. The French Study Group on Sickle Cell Disease,&rdquo; <i>Blood</i>, 1998, 91(12):4472-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/9616141/pubmed\" target=\"_blank\" id=\"9616141\">9616141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute (NHLBI). <i>Hydroxyurea for SIckle Cell Disease: A Systemic Review of Benefits, Harms and Barriers of Utilization</i>, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. <i>Haematologica</i>. 2005;90(2):261-262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/15710584/pubmed\" target=\"_blank\" id=\"15710584\">15710584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodgers GP, Dover GJ, Noguchi CT, et al, &ldquo;Hematologic Responses of Patients With Sickle Cell Disease to Treatment With Hydroxyurea,&rdquo; <i>N Engl J Med</i>, 1990, 322(15):1037-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/1690857/pubmed\" target=\"_blank\" id=\"1690857\">1690857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodgers GP, Dover GJ, Uyesaka N, et al, &ldquo;Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease,&rdquo; <i>N Engl J Med</i>, 1993, 328(2):73-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/ 7677965 /pubmed\" target=\"_blank\" id=\" 7677965 \"> 7677965 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez GI, Kuhn JG, Weiss GR, et al, &quot;A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea,&quot; <i>Blood</i>, 1998, 91(5):1533-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/9473217/pubmed\" target=\"_blank\" id=\"9473217\">9473217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strouse JJ, Heeney MM. Hydroxyrea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. <i>Pediatr Blood Cancer</i>. 2012;59(2):365-371.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/22517797/pubmed\" target=\"_blank\" id=\"22517797\">22517797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strouse JJ, Lanzkron S, Beach MC, et al, &quot;Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children,&quot; <i>Pediatrics</i>, 2008, 122(6):1332-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/19047254/pubmed\" target=\"_blank\" id=\"19047254\">19047254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thornburg CD, Dixon N, Burgett S, et al, &ldquo;A Pilot Study of Hydroxyurea to Prevent Chronic Organ Damage in Young Children With Sickle Cell Anemia,&rdquo; <i>Pediatr Blood Cancer</i>, 2009, 52(5):609-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/19061213/pubmed\" target=\"_blank\" id=\"19061213\">19061213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thornburg CD, Files BA, Luo Z, et al, &ldquo;Impact of Hydroxyurea on Clinical Events in the BABY HUG Trial,&rdquo; <i>Blood</i>, 2012, 120(22):4304-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/22915643/pubmed\" target=\"_blank\" id=\"22915643\">22915643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang WC, Ware RE, Miller ST, et al, &quot;Hydroxycarbamide in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BABY HUG),&quot; <i>Lancet</i>, 2011, 377(9778):1663-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/21571150/pubmed\" target=\"_blank\" id=\"21571150\">21571150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang WC, Wynn LW, Rogers ZR, et al, &ldquo;A Two-Year Pilot Trial of Hydroxyurea in Very Young Children With Sickle Cell Anemia,&rdquo; <i>J Pediatr</i>, 2001, 139(6):790-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/11743503/pubmed\" target=\"_blank\" id=\"11743503\">11743503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ware RE, Despotovic JM, Mortier NA, et al, &quot;Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Hydroxyurea Treatment for Children With Sickle Cell Anemia,&quot; <i>Blood</i>, 2011, 118(18):4985-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/21876119/pubmed\" target=\"_blank\" id=\"21876119\">21876119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. <i>Blood</i>. 2014;124(26):3850-3857.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/25287707/pubmed\" target=\"_blank\" id=\"25287707\">25287707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yan JH, Ataga K, Kaul S, et al. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. <i>J Clin Pharmacol</i>. 2005;45(4):434-445.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/15778424/pubmed\" target=\"_blank\" id=\"15778424\">15778424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimmerman SA, Schultz WH, Davis JS, et al, &ldquo;Sustained Long-Term Hematologic Efficacy of Hydroxyurea at Maximum Tolerated Dose in Children With Sickle Cell Disease,&rdquo; <i>Blood</i>, 2004, 103(6):2039-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-pediatric-drug-information/abstract-text/14630791/pubmed\" target=\"_blank\" id=\"14630791\">14630791</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13367 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708910\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181021\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181022\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047762\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047754\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F180998\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F180983\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F50964559\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047766\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132627\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F181017\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047765\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F181070\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181067\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181005\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F180987\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299494\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F180992\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F181009\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047761\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F180986\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F181004\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10528705\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F181008\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F181010\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13367|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">Hydroxyurea (hydroxycarbamide): Drug information</a></li><li><a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-patient-drug-information\" class=\"drug drug_patient\">Hydroxyurea (hydroxycarbamide): Patient drug information</a></li></ul></div></div>","javascript":null}